Kamada (KMDA) Competitors $6.83 -0.19 (-2.71%) Closing price 04:00 PM EasternExtended Trading$6.80 -0.03 (-0.38%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. EWTX, AUPH, CDTX, PAHC, ARDX, TWST, VERA, AVDL, COGT, and SNDXShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Edgewise Therapeutics (EWTX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Its Competitors Edgewise Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Phibro Animal Health Ardelyx Twist Bioscience Vera Therapeutics Avadel Pharmaceuticals Cogent Biosciences Syndax Pharmaceuticals Kamada (NASDAQ:KMDA) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations. Which has more volatility and risk, KMDA or EWTX? Kamada has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Do insiders & institutionals have more ownership in KMDA or EWTX? 20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is KMDA or EWTX more profitable? Kamada has a net margin of 11.22% compared to Edgewise Therapeutics' net margin of 0.00%. Kamada's return on equity of 7.41% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kamada11.22% 7.41% 5.18% Edgewise Therapeutics N/A -30.65%-29.18% Which has preferable earnings & valuation, KMDA or EWTX? Kamada has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$160.95M2.44$14.46M$0.3420.09Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.84 Do analysts recommend KMDA or EWTX? Kamada presently has a consensus price target of $13.00, suggesting a potential upside of 90.34%. Edgewise Therapeutics has a consensus price target of $40.55, suggesting a potential upside of 195.95%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Does the media refer more to KMDA or EWTX? In the previous week, Edgewise Therapeutics had 2 more articles in the media than Kamada. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 3 mentions for Kamada. Edgewise Therapeutics' average media sentiment score of 1.64 beat Kamada's score of 1.61 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Edgewise Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryKamada beats Edgewise Therapeutics on 10 of the 16 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$403.68M$3.15B$5.78B$10.19BDividend YieldN/A2.33%5.73%4.61%P/E Ratio20.0921.2474.8626.40Price / Sales2.44456.43540.53124.73Price / Cash14.2844.4425.8129.91Price / Book1.519.6413.256.28Net Income$14.46M-$53.20M$3.29B$270.38M7 Day Performance-5.40%0.44%0.47%2.70%1 Month Performance-7.07%4.26%4.60%5.99%1 Year Performance25.09%9.43%73.42%25.94% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada4.543 of 5 stars$6.83-2.7%$13.00+90.3%+28.6%$403.68M$160.95M20.09360Short Interest ↓EWTXEdgewise Therapeutics2.6226 of 5 stars$14.88-4.4%$40.55+172.5%-24.4%$1.64BN/A-9.6060Positive NewsAUPHAurinia Pharmaceuticals2.9018 of 5 stars$12.30-0.8%$12.00-2.4%+81.2%$1.63B$235.13M28.61300News CoveragePositive NewsCDTXCidara Therapeutics3.1625 of 5 stars$62.15-1.6%$64.14+3.2%+449.6%$1.60B$1.27M-5.5890Positive NewsPAHCPhibro Animal Health4.4421 of 5 stars$39.43-0.1%$28.40-28.0%+80.2%$1.60B$1.30B33.422,475Analyst RevisionARDXArdelyx4.6217 of 5 stars$6.59+1.1%$11.70+77.5%+4.8%$1.57B$333.61M-28.6590Positive NewsTWSTTwist Bioscience3.9599 of 5 stars$26.25+1.9%$49.40+88.2%-46.1%$1.55B$312.97M-18.10990VERAVera Therapeutics2.7416 of 5 stars$24.75+2.3%$63.00+154.5%-36.6%$1.54BN/A-6.9140Positive NewsAVDLAvadel Pharmaceuticals3.0869 of 5 stars$15.38-2.4%$20.86+35.6%+12.4%$1.53B$221.08M-512.6770Positive NewsCOGTCogent Biosciences3.0401 of 5 stars$12.68-2.8%$20.00+57.7%+19.1%$1.49BN/A-7.1280Positive NewsSNDXSyndax Pharmaceuticals3.91 of 5 stars$16.33-4.2%$38.89+138.1%-18.7%$1.47B$23.68M-4.20110 Related Companies and Tools Related Companies Edgewise Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Cidara Therapeutics Alternatives Phibro Animal Health Alternatives Ardelyx Alternatives Twist Bioscience Alternatives Vera Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Cogent Biosciences Alternatives Syndax Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
